Phylogica Limited is an Australia-based company principally engaged in provision of drug discovery services to the international pharmaceutical industry utilizing the Company�s Phylomer peptide libraries and screening capabilities. The Company is engaged in the discovery of peptide-based drugs to treat inflammatory diseases. The Company operates in a single geographical location being Australia. The Company has an intellectual property portfolio around its Phylomer peptide libraries and associated technology. The Company acts as a drug discovery partner for the international pharmaceutical industry by offering access to its libraries and through drug discovery deals. Through these deals the Company is entitled to receive payments linked to development progress and the achievement of sales-related targets.